Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SHE:301096)
China · Delayed Price · Currency is CNY 50.66
+0.56 (1.12%)
At close: Feb 3, 2026
SHE:301096 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 589.56 | 801.15 | 1,017 | 607.41 | 374.31 | 207.25 |
Other Revenue | 0.77 | 0.77 | 0.11 | - | - | - |
| 590.33 | 801.92 | 1,017 | 607.41 | 374.31 | 207.25 | |
Revenue Growth (YoY) | -42.41% | -21.18% | 67.51% | 62.27% | 80.61% | 32.50% |
Cost of Revenue | 369.1 | 389.09 | 352.16 | 198.18 | 122.53 | 70.85 |
Gross Profit | 221.23 | 412.83 | 665.28 | 409.23 | 251.78 | 136.4 |
Selling, General & Admin | 128.61 | 95.57 | 139.65 | 104.43 | 57.41 | 48.33 |
Research & Development | 219.39 | 315.15 | 239.64 | 163.03 | 78.33 | 31.73 |
Other Operating Expenses | 25.84 | 9.77 | 5.48 | 10.37 | 0.58 | 0.86 |
Operating Expenses | 408.52 | 458.56 | 404.25 | 286.86 | 140.42 | 82.62 |
Operating Income | -187.29 | -45.73 | 261.04 | 122.37 | 111.36 | 53.77 |
Interest Expense | -20.24 | -16.94 | -7 | -1.32 | -3.67 | -0.64 |
Interest & Investment Income | 7.78 | 13.04 | 28.24 | 42.01 | 2.27 | 1.43 |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | -0 | 1.66 | 1.37 | - |
Other Non Operating Income (Expenses) | 1.19 | 0.78 | -1.9 | -1.56 | -1.36 | -0.16 |
EBT Excluding Unusual Items | -198.54 | -48.84 | 280.37 | 163.16 | 109.98 | 54.41 |
Gain (Loss) on Sale of Investments | 0.99 | -5.59 | -0.11 | -3.97 | -0.65 | - |
Gain (Loss) on Sale of Assets | - | - | 0.78 | 0.02 | - | - |
Asset Writedown | 3.6 | -0.01 | -0.03 | -0.03 | -0.07 | -0.24 |
Other Unusual Items | 35.14 | 18.38 | 14.66 | 31.74 | 9.69 | 10.96 |
Pretax Income | -158.81 | -36.06 | 295.68 | 190.91 | 118.95 | 65.13 |
Income Tax Expense | 29.53 | 16.86 | 23.66 | -3.14 | 7.98 | 7.94 |
Earnings From Continuing Operations | -188.34 | -52.92 | 272.01 | 194.04 | 110.97 | 57.19 |
Minority Interest in Earnings | 0.06 | 0.18 | -0.05 | 0.12 | 0.12 | 0.21 |
Net Income | -188.27 | -52.74 | 271.97 | 194.16 | 111.09 | 57.4 |
Net Income to Common | -188.27 | -52.74 | 271.97 | 194.16 | 111.09 | 57.4 |
Net Income Growth | - | - | 40.07% | 74.78% | 93.52% | 29.29% |
Shares Outstanding (Basic) | 103 | 108 | 108 | 108 | 81 | 81 |
Shares Outstanding (Diluted) | 103 | 108 | 108 | 108 | 81 | 81 |
Shares Change (YoY) | -4.73% | -0.66% | -0.11% | 33.77% | 0.29% | 9.26% |
EPS (Basic) | -1.83 | -0.49 | 2.51 | 1.80 | 1.37 | 0.71 |
EPS (Diluted) | -1.83 | -0.49 | 2.51 | 1.79 | 1.37 | 0.71 |
EPS Growth | - | - | 40.22% | 30.66% | 92.96% | 18.33% |
Free Cash Flow | -278.98 | -590.96 | -598.15 | -332.16 | -103.02 | -200.76 |
Free Cash Flow Per Share | -2.71 | -5.49 | -5.52 | -3.06 | -1.27 | -2.48 |
Dividend Per Share | - | - | 0.300 | 0.800 | 0.600 | - |
Dividend Growth | - | - | -62.50% | 33.33% | - | - |
Gross Margin | 37.48% | 51.48% | 65.39% | 67.37% | 67.27% | 65.81% |
Operating Margin | -31.73% | -5.70% | 25.66% | 20.15% | 29.75% | 25.95% |
Profit Margin | -31.89% | -6.58% | 26.73% | 31.97% | 29.68% | 27.70% |
Free Cash Flow Margin | -47.26% | -73.69% | -58.79% | -54.68% | -27.52% | -96.87% |
EBITDA | -1.6 | 98.04 | 348.93 | 178.67 | 138.97 | 70.6 |
EBITDA Margin | -0.27% | 12.22% | 34.29% | 29.42% | 37.13% | 34.07% |
D&A For EBITDA | 185.68 | 143.77 | 87.89 | 56.3 | 27.61 | 16.83 |
EBIT | -187.29 | -45.73 | 261.04 | 122.37 | 111.36 | 53.77 |
EBIT Margin | -31.73% | -5.70% | 25.66% | 20.15% | 29.75% | 25.95% |
Effective Tax Rate | - | - | 8.00% | - | 6.71% | 12.19% |
Revenue as Reported | 590.33 | 801.92 | 1,017 | 607.41 | 374.31 | 207.25 |
Advertising Expenses | - | 7.34 | 1.72 | 1.38 | 2.75 | 0.41 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.